Related Experiment Video
Updated: Jul 29, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Inhibition of Post-Surgical Tumor Recurrence by 3-Bromopyruvate-Conjugated Gold Nanoclusters via MAPK and PI3K-Akt
Feng Xiao1, Yihang Zhu1, Yao Chen1
1Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, No. 1088 Xueyuan Rd, Nanshan District, Shenzhen, Guangdong 518055, China.
Abstract:
The multitargeted strategy demonstrates significant potential in modern medical treatment, enhancing efficacy and reducing the risk of drug resistance. The rational combination design of nanomaterials and small molecules expands the new prospects of multitargeted therapies. Here, we have covalently linked ligands of atomic gold nanoclusters with 3-bromopyruvate and strategically designed a multitargeted approach to prevent postsurgical melanoma recurrence by activating the mitogen-activated protein kinase pathway and downregulating the phosphatidylinositol 3-kinase pathway. In vitro and in vivo validations confirm safety and outstanding efficacy, with recurrence rates reduced to 0% in completely resected mouse tumor models from 100%. The surface ligand modifiability of gold nanoclusters enables the precise engineering of nanodrugs with a molecule-like structure, providing a novel template that aligns with the clinical translation criteria set by the FDA. These findings identify an effective multitargeted strategy to develop structurally well-defined gold nanocluster-modified drug molecules in preventing postsurgical tumor recurrence.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020